Nascent Biotech Inc. (NBIO)
Market Closed
11 Aug, 20:00
OTCQB OTCQB Primary $
0. 00
0
0%
$
51.66K Market Cap
- P/E Ratio
- Div Yield
15,000 Volume
0 Eps
$ 0
Previous Close Want to track NBIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Nascent Biotech Presents at the July Emerging Growth Conference
Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM BEACH, FL / ACCESSWIRE / July 30, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, is pleased to provide an overview of the Company's presentation at The Emerging Growth Conference on July 18, 2024. Click here to view the Company's entire presentation.
Accesswire | 2 years ago
